Phase 2 N=30 CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=73 Radiation Therapy Alone for the Treatment of Stage 1 and 2 Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Extranodal Marginal Zone Lymphoma
Primary: Relapse-free Survival (RFS) — 83 months
Phase 2 N=56 Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma
Marginal Zone B-cell Lymphoma
Primary: Complete Response Rate (CRR) — 73 Percentage of patients
Phase 2 N=72 Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer
Head and Neck Cancer · Carcinoma, Squamous Cell · Neoplasms, Oral
Primary: Number of Patients With Solitary Elective Volume Recurrence — 0 Participants
N/A N=7 Surgery With or Without Adjuvant Stereotactic Body Radiotherapy
Head and Neck Cancer
Primary: 1-year Local Control — NA; NA months
Phase 2 N=48 Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue
Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Primary: Objective Responses in Patients With MALT Lymphoma Presenting With Measureable Disease — 25; 20; 1 Participants
Phase 2 N=17 Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Primary Mediastinal (Thymic) Large B-Cell Lymphoma · Recurrent Aggressive Non-Hodgkin Lymphoma · Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma
Primary: Overall Response Rate of Pembrolizumab With Concurrent Fractionated External Beam Radiotherapy (EBRT) Among Patients With Relapsed and Refractory Non-Hodgkin Lymphoma…
Phase 2 N=219 Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
Central Nervous System Lymphoma
Primary: Complete Remission Rate After Primary Chemotherapy — 23; 30; 49 Percentage of participants
Phase 2 N=2 Treatment of POEMS Syndrome With Daratumumab
POEMS Syndrome
Primary: Treatment Success — 0 Participants
Phase 2 N=123 Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma
Multiple Myeloma
Primary: Percentage of Patients With MRD(-) Remissions at the Completion of Consolidation Therapy — 81.4 percentage of patients achieving MRD (-)
Phase 2 N=40 Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients
Lymphoma, Non-Hodgkin · Multiple Myeloma
Primary: Overall Participant Counts of Adverse Events (AEs) Up to Twelve Months Post Transplant — 7; 6; 1; 12 participants
Phase 2 N=12 Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas
Non-Hodgkin Lymphoma · Lymphoma · Diffuse Large B-Cell Lymphoma
Primary: Best Overall Response Rate of Pembrolizumab in Participants With Relapsed/Refractory Gray-zone Lymphomas (GZL) and Extra-nodal Diffuse Large B-cell Lymphomas (DLBCL)…
N/A N=21 Molecular and Whole-body MR Imaging in Lymphomas
Lymphoma · Hodgkin Disease · Lymphoma, Non-Hodgkin
Primary: 68Ga-DOTANOC Uptake in Lymphomas With PET/CT — 3.1 Standardized Uptake Value
N/A N=115 ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain
Bone Metastases · Multiple Myeloma
Primary: Number of Responders — 54; 6 Participants
Phase 2 N=30 A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas
Lymphoma, Non-Hodgkin · Lymphoma · Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell
Primary: Overall ObjectiveResponse (ORR) Rate — 0; 7; 19; 4 participants
Phase 4 N=19 Stereotactic Body Radiotherapy for Head and Neck Tumors
Squamous Cell Carcinoma of the Head and Neck · Nasopharyngeal Carcinoma · Salivary Gland Cancer
Primary: Local Control Rate — 1; 5 Participants
Phase 2 N=25 Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma
ISS Stage I Plasma Cell Myeloma · ISS Stage II Plasma Cell Myeloma · ISS Stage III Plasma Cell Myeloma
Primary: Number of Participants With Adverse Events — 8 Participants
Phase 3 N=503 Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
N/A N=12 Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma
Non-Hodgkin's Lymphoma · Lymphoma
Primary: Number of Participants With Complete Response (CR) or Partial Response (PR) — 10; 2 participants
Phase 2 N=23 PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma
B-Cell Lymphoma
Primary: Clinical Response Rate — 1; 7; 0; 8 Participants
Phase 2 N=16 Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Multiple Myeloma
Primary: Number of Participants With Hematologic Response — 7 participants
Phase 2 N=49 Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients
Lymphoma, Non-Hodgkin · Multiple Myeloma
Primary: Number of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE) — 23; 26; 49; 8 participants
Phase 2 N=59 Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
Lymphoma, Mantle-Cell
Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants
Phase 2 N=31 Imaging in MGUS, SMM and MM
Multiple Myeloma · Smoldering Multiple Myeloma · Monoclonal Gammopathy of Undetermined Significance
Primary: Count of Participants With Positive and Negative 18F-FDG PET CT and F18-NaF PET CT Imaging Results in Individuals With MGUS, SMM, and MM. — 0; 1; 5; 10 Participants
Phase 2 N=41 Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
Extramedullary Plasmacytoma · Isolated Plasmacytoma of Bone · Light Chain Deposition Disease
Primary: Median Progression Free Survival (mPFS) — 76.4 months
Phase 3 N=28 Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
Cervical Squamous Cell Carcinoma · Adenosquamous Carcinoma · Adenocarcinoma
Primary: Overall Survival Rate
Phase 2 N=32 Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
Multiple Myeloma
Primary: The Number of Patients That Achieve Complete Response — 7 Participants
N/A N=36 Stereotactic Body Radiotherapy for Spine Tumors
Spinal Metastases · Vertebral Metastases · Benign Spinal Tumors
Primary: Initial Symptom Control — 3; 28; 3; 27 Participants
N/A N=26 Immunotherapy of the Paraneoplastic Syndromes
Paraneoplastic Syndromes
Primary: Survival of Patients With Paraneoplastic Disease Who Are Treated With Tacrolimus — 48 months
N/A N=52 Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
Lymphoma
Primary: Total Number of Participants Who Experienced Acute Treatment Related Adverse Events — 52 Participants